These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 10408808

  • 1. Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier.
    Poduslo JF, Curran GL, Sanyal B, Selkoe DJ.
    Neurobiol Dis; 1999 Jun; 6(3):190-9. PubMed ID: 10408808
    [Abstract] [Full Text] [Related]

  • 2. Permeability and residual plasma volume of human, Dutch variant, and rat amyloid beta-protein 1-40 at the blood-brain barrier.
    Poduslo JF, Curran GL, Haggard JJ, Biere AL, Selkoe DJ.
    Neurobiol Dis; 1997 Jun; 4(1):27-34. PubMed ID: 9258909
    [Abstract] [Full Text] [Related]

  • 3. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease.
    Poduslo JF, Curran GL, Wengenack TM, Malester B, Duff K.
    Neurobiol Dis; 2001 Aug; 8(4):555-67. PubMed ID: 11493021
    [Abstract] [Full Text] [Related]

  • 4. Beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma.
    Poduslo JF, Curran GL, Kumar A, Frangione B, Soto C.
    J Neurobiol; 1999 Jun 05; 39(3):371-82. PubMed ID: 10363910
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation.
    Kandimalla KK, Curran GL, Holasek SS, Gilles EJ, Wengenack TM, Poduslo JF.
    J Pharmacol Exp Ther; 2005 Jun 05; 313(3):1370-8. PubMed ID: 15743932
    [Abstract] [Full Text] [Related]

  • 7. Blood-brain barrier transport of circulating Alzheimer's amyloid beta.
    Zlokovic BV, Ghiso J, Mackic JB, McComb JG, Weiss MH, Frangione B.
    Biochem Biophys Res Commun; 1993 Dec 30; 197(3):1034-40. PubMed ID: 8280117
    [Abstract] [Full Text] [Related]

  • 8. Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier.
    Ito S, Ohtsuki S, Terasaki T.
    Neurosci Res; 2006 Nov 30; 56(3):246-52. PubMed ID: 16926058
    [Abstract] [Full Text] [Related]

  • 9. Lack of brain-to-blood efflux transport activity of low-density lipoprotein receptor-related protein-1 (LRP-1) for amyloid-beta peptide(1-40) in mouse: involvement of an LRP-1-independent pathway.
    Ito S, Ueno T, Ohtsuki S, Terasaki T.
    J Neurochem; 2010 Jun 30; 113(5):1356-63. PubMed ID: 20367755
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Drug targeting to the brain using avidin-biotin technology in the mouse; (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease).
    Jeong Lee H, Pardridge WM.
    J Drug Target; 2000 Jun 30; 8(6):413-24. PubMed ID: 11328667
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Poor permeability of morphine 3-glucuronide and morphine 6-glucuronide through the blood-brain barrier in the rat.
    Bickel U, Schumacher OP, Kang YS, Voigt K.
    J Pharmacol Exp Ther; 1996 Jul 30; 278(1):107-13. PubMed ID: 8764341
    [Abstract] [Full Text] [Related]

  • 14. Enhanced permeabilities of cationized-bovine serum albumins at the blood-nerve and blood-brain barriers in awake rats.
    Wadhwani KC, Shimon-Hophy M, Rapoport SI.
    J Neurosci Res; 1992 Jul 30; 32(3):407-14. PubMed ID: 1433388
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Brain iron homeostasis.
    Moos T.
    Dan Med Bull; 2002 Nov 30; 49(4):279-301. PubMed ID: 12553165
    [Abstract] [Full Text] [Related]

  • 17. Brain to blood efflux transport of adenosine: blood-brain barrier studies in the rat.
    Isakovic AJ, Abbott NJ, Redzic ZB.
    J Neurochem; 2004 Jul 30; 90(2):272-86. PubMed ID: 15228584
    [Abstract] [Full Text] [Related]

  • 18. In vivo and in vitro evidence for nonrestricted transport of 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein tetraacetoxymethyl ester at the blood-brain barrier.
    Hirohashi T, Terasaki T, Shigetoshi M, Sugiyama Y.
    J Pharmacol Exp Ther; 1997 Feb 30; 280(2):813-9. PubMed ID: 9023295
    [Abstract] [Full Text] [Related]

  • 19. Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease.
    Matsumoto Y, Yanase D, Noguchi-Shinohara M, Ono K, Yoshita M, Yamada M.
    Dement Geriatr Cogn Disord; 2007 Feb 30; 23(4):241-5. PubMed ID: 17310121
    [Abstract] [Full Text] [Related]

  • 20. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding.
    Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA, Van Deusen J.
    J Pharmacol Exp Ther; 2005 Jun 30; 313(3):1254-62. PubMed ID: 15743928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.